Abstract: The present invention includes methods for selecting a therapy for improved cognition as well as prevention of cognitive loss/dysfunction using one or more endophenotypes comprising: obtaining a sample from a subject; measuring biomarkers that differentiate between an inflammatory, a metabolic, a neurotrophic, and a depressive endophenotype; and selecting a course of treatment for the subject based on whether the subject is scored as having a high or a low endophenotype for one or more of the inflammatory, a metabolic, a neurotrophic, and a depressive endophenotypes.

Abstract: In one aspect, the present disclosure provides GlcNAc-Asn analogs of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of using the compounds disclosed herein. Additionally, the present disclosure also provides methods of treating cancer comprising inhibiting NGLY1.

Abstract: In one aspect, the present disclosure provides GlcNAc-Asn analogs of the formula (I): wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of using the compounds disclosed herein. Additionally, the present disclosure also provides methods of treating cancer comprising inhibiting NGLY1.

Abstract: Certain embodiments are directed to modified or variant Cas9 proteins, and/or methods of using the same.

Abstract: The present disclosure relates to devices, systems, and methods for modeling ocular translaminar pressure gradients ex vivo. A first fluid pressure level can be applied to a first side of a wall of donor eye cup (e.g., a posterior human eye cup) to simulate intracranial pressure (ICP), for example around the optical nerve head (ONH), and a second fluid pressure level can be applied to a second side of the wall of the donor eye cup to simulate intraocular pressure (IOP). These devices, systems, and methods are unique in that they allow ex vivo modeling of dynamic changes in translaminar pressure gradients.

Abstract: The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNF? biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.

Abstract: Certain embodiments are directed to methods of treating or preventing an addictive behavior in a subject, said method comprising administering to said subject an effective amount of a DMTU or a composition comprising same.

Abstract: A system for measuring and controlling foot temperature. The system comprises a heating or cooling device including one or more sealed fluidic pathways having a cooling or heating fluid therein and disposed in or on an article of footwear or a sock. A pumping device coupled to the heating or cooling device is configured to circulate the fluid in the one or more sealed fluidic pathways. A heat exchanger coupled to the heating or cooling device is configured to remove or add heat from or to the fluid in the one or more sealed fluidic pathways. A controller coupled to the pumping device and the heat exchanger is configured to control the pumping device and the heat exchanger to cool or heat a foot located inside the article of footwear or the sock.

Abstract: In some aspects, the present disclosure provides compounds of the formulae: (A), (B), (III), and/or (IV), wherein the variables are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, the compounds or compositions of the present disclosure may be used for the treatment of diseases or disorders, such as eye diseases and peripheral arterial diseases such as hind limb ischemia.

Abstract: The subject invention provides methods of treating neurological disease or disorder, such as brain injuries, such as stroke, traumatic brain injury (TBI), or other ischemic events that cause brain injury by inhibiting or down-regulating Let-7i activity or function. The disclosed methods may have the potential to extend the “window of opportunity” for treatment of such injuries and enhance the effectiveness of existing therapeutics.

Abstract: Certain embodiments are directed to methods for making programmable bioinspired nanoparticles (P-BiNP). Nanoparticles are coated with a cell membrane derived from a cell stimulated to express or overexpress a protein identified as being expressed in a target cell, forming a homotypic and organ targeted nanoparticle delivery vehicle.

Abstract: Dual-layer insole apparatuses for diabetic foot lesion prevention and related methods are provided. Some insole apparatuses have a body defining a plurality of cavities configured to be coupled to a fluid source. The fluid source can deliver fluid to vary internal pressures of the cavities. The body further defines an insole-shaped structure.

Abstract: Certain embodiments are directed to methods of treating LLT1 expressing cancer by administering to a subject having an LLT1 expressing cancer an LLT1 inhibitor.

Abstract: In one aspect, the present disclosure provides GlcNAc-Asn analogs of the formula (I): wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of using the compounds disclosed herein. Additionally, the present disclosure also provides methods of treating cancer comprising inhibiting NGLY1.

Abstract: The present invention includes a composition and method for the treatment of an eye disease comprising a therapeutically effective amount of an autophagy stimulator that treats or slows the progression of the eye disease by enhancing or stimulating autophagy or correcting an autophagy deficiency.

Abstract: The present invention related to compounds, compositions, methods of use, and processes for preparing compound which are useful as deterrents for terrestrial arthropods and marine organisms.

Abstract: The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, ?2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-?), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.

Abstract: The present invention includes a composition and method for the treatment of an eye disease comprising a therapeutically effective amount of an autophagy stimulator that treats or slows the progression of the eye disease by enhancing or stimulating autophagy or correcting an autophagy deficiency.

Abstract: Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165 (165Ho) and dysprosium-164 (164Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particles and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandage coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).

Abstract: Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165 (165Ho) and dysprosium-164 (164Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particles and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandage coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).